文献速递冠心病血脂与心血管预防

阿利西尤单抗对心肌梗死类型的影响:ODYSSEY OUTCOMES 试验的启示

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
PubMed 文献 · Eur Heart J · 2019-01-01

ODYSSEY OUTCOMES 试验纳入 18 924 例近期急性冠脉综合征且强化他汀治疗后 LDL-C 仍≥1.8 mmol/L 的患者,比较 PCSK9 抑制剂阿利西尤单抗与安慰剂。预设分析显示,阿利西尤单抗降低首次心梗风险(HR 0.85,95%CI 0.77-0.95;P=0.003),主要减少 1 型和 2 型心梗,对 4 型心梗无影响。

要点

  • 阿利西尤单抗降低 1 型心梗风险(HR 0.87,95%CI 0.77-0.99;P=0.032)。
  • 阿利西尤单抗降低 2 型心梗风险(HR 0.77,95%CI 0.61-0.97;P=0.025)。
  • 未观察到对 4 型心梗的显著影响。

核心结论

  • 急性冠脉综合征后,在强化他汀治疗基础上加用阿利西尤单抗可减少 1 型和 2 型心肌梗死。
  • 数据首次提示降脂治疗可降低 2 型心肌梗死风险。

研究设计与样本

  • ODYSSEY OUTCOMES 试验的预设分析,纳入 18 924 例近期急性冠脉综合征且强化他汀治疗后 LDL-C≥1.8 mmol/L 的患者。
  • 比较 PCSK9 抑制剂阿利西尤单抗与安慰剂,中位随访 2.8 年。
  • 心肌梗死类型经前瞻性判定和分类。

主要发现

  • 共 1860 例心肌梗死,其中 1 型 1223 例(65.8%),2 型 386 例(20.8%),4 型 244 例(13.1%)。
  • 3 型仅 2 例,5 型仅 5 例。
  • 阿利西尤单抗降低首次心梗风险(HR 0.85,95%CI 0.77-0.95;P=0.003)。
  • 1 型心梗风险降低(HR 0.87,95%CI 0.77-0.99;P=0.032)。
  • 2 型心梗风险降低(HR 0.77,95%CI 0.61-0.97;P=0.025),4 型心梗无显著变化。

临床怎么用

  • 对近期急性冠脉综合征且强化他汀治疗后 LDL-C 仍≥1.8 mmol/L 的患者,可考虑加用阿利西尤单抗以降低 1 型和 2 型心梗风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin-kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. METHODS AND RESULTS: Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77-0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77-0.99; P = 0.032) and Type 2 (0.77, 0.61-0.97; P = 0.025), but not Type 4 MI. CONCLUSION: After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. White HD, Steg PG, Szarek M, et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. Eur Heart J. 2019. PMID: 31121022. doi:10.1093/eurheartj/ehz299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。